Leadership

Our leadership, including the management team and Board of Directors, is made up of venture capital investing,  AI technology, biotechnology and pharmaceutical industry experts who are recognized for their contributions to discovering and developing new therapies and their track record of successfully bringing creating and managing AI-Enabled drug discovery startups.  

---

Board Members & Advisors

---

AI Engine & Platform Team

Ailynix AI Team conducts research on biology systems and generates enormous amounts of data, which needs to be stored, processed and analyzed, mapping data, originated from various experiments and associations, allowing to derive hidden data patterns, find dependencies and associations unknown before, proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. Our Deep Learning (DL) is a system that involves training systems called artificial neural networks on lots of information derived from key data inputs, and then introducing new information to the mix. Predictive modeling of biological processes and drugs becomes significantly more sophisticated and widespread. By leveraging the diversity of available molecular and clinical data, predictive modeling could help identify new potential-candidate molecules with a high probability of being successfully developed into drugs that act on biological targets safely and effectively.

---

Drug Discovery Team

We partner with University Labs and CRO’s to deliver experimentally validated novel chemical matter. We combine molecular simulations, machine learning and high performance computing algorithms to perform structure-based drug design.  Our platform allows our partners to leverage their proprietary wet-lab technologies to interrogate biology in new ways.